01.25.06
Abbott
4Q Revenues: $6 billion (+7%)
4Q Earnings: $976 million (flat)
FY Revenues: $22.3 billion (+13.5%)
FY Earnings: $3.4 billion (+4%)
Comments: Abbott achieved records sales for the quarter and the year. Pharmaceutical Products Group sales grew 10% in the quarter, driven by performance of Humira and contributions from TriCor and Omnicef. Worldwide sales of Humira were $1.4 billion for the year, up 64%. R&D spend was up 7% for the year to $1.8 billion.
4Q Revenues: $6 billion (+7%)
4Q Earnings: $976 million (flat)
FY Revenues: $22.3 billion (+13.5%)
FY Earnings: $3.4 billion (+4%)
Comments: Abbott achieved records sales for the quarter and the year. Pharmaceutical Products Group sales grew 10% in the quarter, driven by performance of Humira and contributions from TriCor and Omnicef. Worldwide sales of Humira were $1.4 billion for the year, up 64%. R&D spend was up 7% for the year to $1.8 billion.